Wall Street Zen Upgrades KORU Medical Systems (NASDAQ:KRMD) to Strong-Buy

KORU Medical Systems (NASDAQ:KRMD) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Monday.

KRMD has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a report on Wednesday, October 8th. Lake Street Capital raised their price objective on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Canaccord Genuity Group boosted their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.13.

KORU Medical Systems Trading Down 1.9%

KRMD opened at $5.78 on Monday. KORU Medical Systems has a 52 week low of $1.86 and a 52 week high of $6.61. The company has a quick ratio of 1.92, a current ratio of 2.48 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $5.38 and a 200-day simple moving average of $4.41. The firm has a market cap of $267.73 million, a P/E ratio of -72.25 and a beta of 0.51.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its position in KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after purchasing an additional 158,914 shares in the last quarter. Acuitas Investments LLC acquired a new position in KORU Medical Systems during the second quarter valued at approximately $1,441,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in KORU Medical Systems by 23.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 82,631 shares of the company’s stock worth $296,000 after buying an additional 15,714 shares during the period. Archon Capital Management LLC grew its stake in KORU Medical Systems by 23.5% during the second quarter. Archon Capital Management LLC now owns 700,147 shares of the company’s stock worth $2,507,000 after buying an additional 133,277 shares during the period. Finally, Invesco Ltd. purchased a new position in shares of KORU Medical Systems in the 2nd quarter valued at $80,000. 58.60% of the stock is owned by institutional investors and hedge funds.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.